NYSE: $PFE
NEW YORK–(BUSINESS WIRE) October 26, 2026 — Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) to the treatment of…
Source: Read More